CanSino Biologics Inc.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 2009-01-13

Employees: 1.4K

Market Cap: -

Website: http://www.cansinotech.com

Introduction: The company was founded in 2009 in China. It is an industry-leading high-tech biological products company with the mission of providing solutions for the prevention and treatment of infectious diseases worldwide, focusing on the R&D, production and commercialization of innovative, high-quality, and accessible human vaccines. Cansino Biotech's mission has always been to “provide the world with innovative, high-quality, and accessible vaccines” to achieve the corporate vision of “endless innovation, a world free of diseases”. The company is an innovative vaccine enterprise dedicated to the development, production and commercialization of innovative vaccines that meet Chinese and international standards. The marketed products and product pipeline cover the prevention of meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, shingles, tuberculosis, and many other vaccine varieties with high clinical demand. The main products are MCV4, MCV2, AD5-nCoV, inhaled AD5-nCoV and xBB.1.5 variant vaccines, AD5-eBoV, etc. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperation and Development Base, Tianjin Model Group, etc.

Clinical Trials

Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine

Phase 3

Recruiting

Conditions: Diphtheria, Tetanus and Acellular Pertussis

Interventions: Biological: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 1)
Biological: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 2)
Biological: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 3)

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-30

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 780

Registration Number: NCT06857370

Locations: 🇨🇳
Changge Center for Disease Control and Prevention, Xuchang, Henan, China

A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years

Phase 1

Not yet recruiting

Conditions: Tuberculosis

Interventions: Biological: Tuberculosis (TB) vaccine (Ad5-105K)
Biological: Placebo
Biological: Ad5-105K

First Posted Date: 2024-12-13

Last Posted Date: 2024-12-13

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 36

Registration Number: NCT06732583

A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)

Phase 2

Active, not recruiting

Conditions: Diphtheria
Tetanus
Pertussis

Interventions: Biological: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp))
Biological: 23-valent Pneumococcal Polysaccharide Vaccine (PPV23)
Biological: Tdcp
Biological: PPV23
Biological: Diphtheria-tetanus-acellular pertussis vaccine (DTaP)

First Posted Date: 2024-11-27

Last Posted Date: 2025-03-17

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 1820

Registration Number: NCT06708286

Locations: 🇨🇳
Kaihua County Center for Disease Control and Prevention, Kaihua, China

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds

Phase 3

Active, not recruiting

Conditions: Meningococcal Meningitis

Interventions: Biological: MCV4
Biological: MPSV4

First Posted Date: 2024-11-21

Last Posted Date: 2025-03-17

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 840

Registration Number: NCT06700148

Locations: 🇨🇳
Kaifeng Center for Disease Control and Prevention, Kaifeng, China
🇨🇳
Dengfeng Center for Disease Control and Prevention, Dengfeng, China

Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine

Phase 1

Recruiting

Conditions: Haemophilus Influenzae Type B Infection

Interventions: Biological: Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
Biological: Haemophilus Influenzae Type b Conjugate Vaccine

First Posted Date: 2024-10-01

Last Posted Date: 2024-12-04

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 160

Registration Number: NCT06621654

Locations: 🇨🇳
Jiulongpo District Center for Disease Control and Prevention, Chongqing, China

A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers

Phase 1

Not yet recruiting

Conditions: Poliomyelitis

Interventions: Biological: VLP-Polio high dose
Biological: Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose
Biological: VLP-Polio medium dose
Biological: Vaccine Poliomyelitis Inactivated (IPV)

First Posted Date: 2024-08-29

Last Posted Date: 2024-08-29

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 480

Registration Number: NCT06577298

Locations: 🇮🇩
Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

Phase 4

Recruiting

Conditions: Epidemic Meningitis

Interventions: Biological: MCV4

First Posted Date: 2024-04-29

Last Posted Date: 2024-06-24

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 3000

Registration Number: NCT06389513

Locations: 🇨🇳
Nanjing Luhe District Center for Disease Control and Prevention Center for Disease Control and Prevention, Nanjing, China

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Phase 3

Active, not recruiting

Conditions: Meningococcal Meningitis

Interventions: Biological: MPSV4
Biological: MCV4

First Posted Date: 2024-01-26

Last Posted Date: 2025-03-21

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 840

Registration Number: NCT06226714

Locations: 🇨🇳
Jiangjin District Center for Disease Control and Prevention, Chongqing, China
🇨🇳
Wanzhou District Center for Disease Control and Prevention, Chongqing, China
🇨🇳
Yuzhong District Center for Disease Control and Prevention, Chongqing, China

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Phase 3

Active, not recruiting

Conditions: Meningococcal Meningitis

Interventions: Biological: batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)
Biological: batch 3 of MCV4
Biological: Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological: batch 2 of MCV4